Medeligo vs NephRef
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
Medeligo
Access the latest oncology research and treatment information instantly. This app features AI-powered search, real-time updates from trusted sources, and covers over 2,000 cancer types. Quickly find literature, videos, and images to prepare for patient care and answer complex questions.
- AI-powered search
- Real-time oncology information
- Covers 2,000+ cancer types
- Access to literature, videos, and images
- Trusted medical journal searches
- Save, share, and print articles
Read full descriptionHide full description
Medeligo® provides instant access to the latest oncology literature and information for treatment, procedure, testing, and management information across all oncology subspecialties. FINGERTIP ACCESS TO THE LATEST ONCOLOGY INFORMATION - AI-powered search engineered by technologists and medical librarians - Effortless UI gets to answers in seconds - Covers more than 2,000 solid tumors and cancers, including the WHO Classification of Tumours - Real-time searches provide the latest information available - Searches only the most trusted medical journals, databases, and information resources - Primary source material: unfiltered, unbiased, uncurated Benefits include: - Find and read the latest oncology literature in seconds - Watch relevant videos and browse images - Prepare for patient rounds, consults, and surgeries - Answer patient-specific questions quickly at tumor boards - Share, print, or save articles Limited introductory price of $49.99 (Reg. $149.99) for the All Access (1 year) subscription — includes a risk-free 3-month trial. To learn more, please visit www.medeligo.com. After the free trial period, your subscription will continue for $49.99/year, and your iTunes account will be charged. If you do not wish to continue your subscription after your free trial ends, turn off auto-renew in your Account Settings 24 hours before the end of your free trial. Subscriptions will automatically renew when they expire unless you turn off auto-renew at least 24 hours before the end of your subscription period. Your account will be charged $49.99 for renewal within 24 hours before the end of your subscription period. You can manage your subscription and turn off auto-renew by going to your Account Settings. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable. You can read more about our terms and conditions here: Privacy policy: http://medeligo.com/privacy-policy/ Terms of service: http://medeligo.com/terms-of-service/
NephRef
This medical reference tool aids physicians and advanced practitioners in managing patients with kidney disease. It provides quick access to educational resources and guidance on patient referral, urgency, and interval management.
- Kidney disease patient care guidance
- Referral management
- Urgency assessment
- Interval management
- Educational resources access
Read full descriptionHide full description
NephRef is both a reference and referral tool designed to educate and empower physicians and advanced practitioners in their care and referral of patients with kidney disease. Conceived and developed by the Section of Nephrology in the Department of Medicine at West Virginia University School of Medicine, NephRef offers a quick and easy link to educational resources and provides information about urgency and interval management of patients referred for specialty consultation. NephRef is an educational tool only. Not for individual patient diagnosis or treatment.
Screenshots
Verdict
The clearest difference is in-app purchases: NephRef at none against Medeligo's 1. NephRef also leads on ads (none vs shown) and update cadence (every 10 days vs every 5 months). Medeligo's advantage is ratings volume (9 vs 1). On price, rating and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Medeligo sells 1 in-app purchase, starting at $24.99 per year. NephRef asks for nothing beyond the download.
On the App Store both sit at effectively the same score — 5.0 for Medeligo against 5.0 for NephRef. That said, the two scores are not equally well evidenced: Medeligo has 9 ratings behind it against 1, so its average is the more settled of the two.
Medeligo ships an update every 5 months, NephRef every 10 days. The most recent releases landed on October 5, 2026 and September 18, 2026 respectively.
| Parameter | Medeligo | NephRef |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (9 ratings) | 5.0 (1 ratings) |
| Positive reviews | 100.0% of reviews | — |
| Number of ratings | 9 — better | 1 |
| Update frequency | Every 5 months | Every 10 days — better |
| Ads | Yes | No — better |
| In-app purchases | Yes | No — better |
| Monetization | Free with in-app purchases | Free — better |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 14.0 | 11.0 — better |
| Further details — not scored | ||
| Size | 4 MB | 44 MB |
| Age rating | 17+ | 12+ |
| Developer | LiveMed Media Ltd. | Media Foundations LLC |
Customer experience
Medeligo
NephRef
In-app purchases
Medeligo
- All Access (1 year)3 Months trial$24.991 Year
NephRef
No in-app purchases
Questions
Is Medeligo free?
Is NephRef free?
Which has better reviews, Medeligo or NephRef?
Do Medeligo or NephRef have ads?
Which is updated more often, Medeligo or NephRef?
Other comparisons
